To validate the hypothesis that pharmacological inhibition of SLC6A19 is sufficient to reduce the pathological blood Phe levels in the Pahenu2 mouse model of PKU, plasma samples were analyzed by LC-MS/MS. The gene discussed is SLC6A19; the disease is phenylketonuria.